Suven Life Sciences Limited
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities in central nervous system diseases. Its product candida… Read more
Suven Life Sciences Limited (SUVEN) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.368x
Based on the latest financial reports, Suven Life Sciences Limited (SUVEN) has a cash flow conversion efficiency ratio of -0.368x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₹-1.03 Billion) by net assets (₹2.81 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Suven Life Sciences Limited - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Suven Life Sciences Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Suven Life Sciences Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Suven Life Sciences Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ONWARD MEDICAL BV EO -12
F:63E
|
N/A |
|
Chen Full International Co Ltd
TWO:8383
|
-0.027x |
|
CSB Bancorp Inc
PINK:CSBB
|
0.046x |
|
Ovid Therapeutics Inc
NASDAQ:OVID
|
-0.288x |
|
Steel Partners Holdings LP
NYSE:SPLP
|
-0.004x |
|
Omega Flex Inc
NASDAQ:OFLX
|
0.032x |
|
Konya Cimento Sanayi AS
IS:KONYA
|
-0.051x |
|
HIL Limited
NSE:HIL
|
0.049x |
Annual Cash Flow Conversion Efficiency for Suven Life Sciences Limited (2005–2025)
The table below shows the annual cash flow conversion efficiency of Suven Life Sciences Limited from 2005 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | ₹1.10 Billion | ₹-1.48 Billion | -1.350x | -215.69% |
| 2024-03-31 | ₹2.70 Billion | ₹-1.15 Billion | -0.428x | -55.59% |
| 2023-03-31 | ₹3.75 Billion | ₹-1.03 Billion | -0.275x | +79.28% |
| 2022-03-31 | ₹961.45 Million | ₹-1.28 Billion | -1.327x | -49.20% |
| 2021-03-31 | ₹1.08 Billion | ₹-960.24 Million | -0.889x | +34.25% |
| 2020-03-31 | ₹1.43 Billion | ₹-1.94 Billion | -1.352x | -3261.03% |
| 2019-03-31 | ₹8.31 Billion | ₹355.49 Million | 0.043x | -53.06% |
| 2018-03-31 | ₹7.67 Billion | ₹699.36 Million | 0.091x | -44.15% |
| 2017-03-31 | ₹6.67 Billion | ₹1.09 Billion | 0.163x | +39.04% |
| 2016-03-31 | ₹5.95 Billion | ₹698.78 Million | 0.117x | -54.10% |
| 2015-03-31 | ₹5.59 Billion | ₹1.43 Billion | 0.256x | -44.27% |
| 2014-03-31 | ₹2.64 Billion | ₹1.21 Billion | 0.459x | +130.90% |
| 2013-03-31 | ₹1.54 Billion | ₹306.86 Million | 0.199x | -24.39% |
| 2012-03-31 | ₹1.28 Billion | ₹335.07 Million | 0.263x | +503.70% |
| 2011-03-31 | ₹1.27 Billion | ₹55.16 Million | 0.044x | -60.24% |
| 2010-03-31 | ₹1.18 Billion | ₹129.25 Million | 0.109x | -63.45% |
| 2009-03-31 | ₹1.14 Billion | ₹342.73 Million | 0.299x | +709.03% |
| 2008-03-31 | ₹1.06 Billion | ₹39.38 Million | 0.037x | -76.86% |
| 2007-03-31 | ₹1.02 Billion | ₹162.41 Million | 0.160x | +161.76% |
| 2006-03-31 | ₹902.12 Million | ₹55.13 Million | 0.061x | +135.07% |
| 2005-03-31 | ₹811.85 Million | ₹21.11 Million | 0.026x | -- |